Linvoseltamab plus tocilizumab for heavily treated multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a combination of two drugs (linvoseltamab and tocilizumab) for adults with multiple myeloma that has stopped responding to standard treatments. Tocilizumab is added to help reduce serious side effects from the main drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your myeloma must have progressed despite at least 4 previous treatment regimens
- Your previous treatments must have included a protease inhibitor, an immunomodulatory drug (like lenalidomide or pomalidomide), and an anti-CD38 antibody (like daratumumab)
- Your disease must be progressing now or recently (confirmed by imaging or blood work)
- You must be well enough for outpatient treatment (ECOG score of 0, 1, or 2)
- You cannot have plasma cell leukemia, amyloidosis, or certain other rare blood disorders
- You cannot have brain lesions from myeloma, myeloma involving the brain lining, or certain nerve/brain conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares linvoseltamab against a standard combination (elotuzumab + pomalidomide + dexamethasone) in adults with multiple myeloma that has returned or not responded. It aims to find out whether linvoseltamab works better and is safe for people who have already had some myeloma treatments.
This trial tests whether REGN17372 plus linvoseltamab is safe for people with multiple myeloma that has come back or not responded to prior treatments. You may join if you have tried at least 3 other therapies.
This trial tests a new drug called linvoseltamab combined with other cancer treatments for people with multiple myeloma that has stopped responding to standard therapies. It may be an option if you have already tried several treatments and are looking for a new approach.
This trial tests linvoseltamab (a new targeted immune treatment) to see if it’s safe and how well it works in adults with recently diagnosed multiple myeloma who haven’t started treatment yet. Because it’s a “window of opportunity” study, it’s meant to learn early results before standard therapy is fully underway.
This trial tests a new drug called linvoseltamab for people with AL amyloidosis that has returned or is not responding to treatment. It aims to see if the drug is safe and helps control the disease.
This trial tests linvoseltamab, an experimental antibody medicine, in adults whose multiple myeloma has come back or does not respond to treatment. It may help some people by targeting myeloma cells after multiple prior therapies have failed.
Hear when a new Relapsed/Refractory Multiple Myeloma (RRMM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.